107 related articles for article (PubMed ID: 27380644)
1. PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy.
Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
Ann Surg Oncol; 2016 Nov; 23(12):4093-4100. PubMed ID: 27380644
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
[TBL] [Abstract][Full Text] [Related]
5. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
6. Stromal PDGFR-β Expression is Associated with Postoperative Survival of Non-Small Cell Lung Cancer Patients Receiving Preoperative Chemo- or Chemoradiotherapy Followed by Surgery.
Kanzaki R; Ose N; Kawamura T; Funaki S; Shintani Y; Minami M; Takakura N; Okumura M
World J Surg; 2018 Sep; 42(9):2879-2886. PubMed ID: 29511870
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
9. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of PSF1 as a prognostic biomarker for prostate cancer.
Tahara H; Naito H; Kise K; Wakabayashi T; Kamoi K; Okihara K; Yanagisawa A; Nakai Y; Nonomura N; Morii E; Miki T; Takakura N
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):56-62. PubMed ID: 25403418
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
13. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
[TBL] [Abstract][Full Text] [Related]
18. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
20. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
Li GF; Deng SJ; Weng WW; Guo G; Chen N
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
